SL Green Inks 123,000 Square Foot Lease With the Travelers Insurance Company at 485 Lexington Avenue
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced […]
TSX News -
TDb Split Corp. Class A Share Consolidation
TORONTO, Dec. 09, 2024 (GLOBE NEWSWIRE) — TDb Split Corp. (the “Company”) announces a Class A share consolidation. The recent […]
VR Resources Signs MOU with Lac Des Milles Lacs First Nation, Northwestern Ontario
VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) — VR Resources Ltd. (TSX.V: VRR; OTC:VRRCF; FSE: 5VR), (the “Company” or […]
SL Green Announces Transactions at 100 Park Avenue
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) — SL Green Realty Corp. (NYSE: SLG), Manhattan’s largest office landlord, today announced […]
Chart Industries to Present at Wells Fargo 23rd Annual Midstream, Energy & Utilities Symposium
ATLANTA, Dec. 09, 2024 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”), a global leader in clean energy and […]
Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China’s NMPA
ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. […]
Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering
Jiangxi, China, Dec. 09, 2024 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (Nasdaq: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical […]
CytoSorbents Announces Rights Offering
PRINCETON, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions […]
FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Designation based on encouraging Phase 1b clinical data, including that SER-155 resulted in a 77% relative risk reduction in bacterial […]
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) — Olema […]
